Pigmented lesions are hypermelanocytic areas typically induced by sun exposure, the natural aging process or congenital factors. Pigmented lesions vary widely in size, shape and depth. They can be either raised or flat and are usually a cosmetic rather than a medical concern. Intense Pulsed Light (IPL) which targets the melanin is effective in treating benign lesions and clearing them.

Patented Lumenis Optimal Pulse Technology (OPT) becomes the first IPL approved for management of dry eye disease due to MGD, and Lumenis launches OptiLight.

Lumenis Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce its latest innovation, the NuEra Tight with FocalRF technology. The platform introduces a breakthrough in personalized non-invasive RF body treatments to match the unique needs of every patient

Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical Business to Boston Scientific (NYSE: BSX) in a transaction valued at USD1.07 billion, subject to closing adjustments.

Tattoo inks are made of solid colored particles, which can be targeted and eliminated by dedicated lasers in the similar manner as pigmented lesions. Different tattoos might require different types of laser in order to remove them, depending on the type of ink, the color, and the depth of the tattoo. Q-Switch lasers release high-powered pulses of extremely short duration. The intense and rapid heating induced by light absorption leads to a photo-thermal effect. As the chromophore is heated, it undergoes sudden thermal expansion generating shock waves audible as a popping sound with each laser pulse. This photo-acoustic effect generates forces that allow fragmenting tattoo pigment particles. The pigment treated this way gradually becomes shallower over time until it fades away. The peripheral tissues remain unaltered making the treatment selective and safe.

Leg veins, spider veins and other visible benign vascular lesions are common aesthetic conditions for which patients seek treatment for both medical and cosmetic reasons. Lasers and other light based technologies enable effective treatment of leg veins and vascular lesions by inducing vessel collapse through coagulation with minimal damage to adjacent structures.

“Baring Private Equity Asia today announced that its affiliated private equity funds (“BPEA”) have agreed to acquire Lumenis”

Lumenis expands FoLix™, the FDA & Health Canada-cleared fractional laser for hair loss, into Canada. Named ‘Best Laser Treatment for Hair Loss’ by NewBeauty

Lumenis Unveils Enhanced SPLENDOR XTM Laser Hair Removal Solution with New Clinical Data at the Annual American Society for Laser Medicine and Surgery (ASLMS) Conference New data demonstrates effectiveness of

Lumenis will refocus and accelerate planned investments to support the development of its fast-growing Aesthetic and Vision businesses, emphasizing R&D, global sales and marketing channels, and business development activities.